Tags

Type your tag names separated by a space and hit enter

Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Cancer. 2003 Dec 15; 98(12):2547-53.C

Abstract

BACKGROUND

HER-2/neu is a valuable prognostic marker in primary breast carcinoma. Controversy surrounds the correlation between HER-2/neu expression and other prognostic markers, as has been discussed in preclinical and clinical studies. The objective of the current study was to investigate the probability, calculated using parameters that are assessed routinely in clinical practice, that patients with breast carcinoma had positive HER-2/neu status.

METHODS

The authors evaluated HER-2/neu status in 923 consecutive patients with breast carcinoma by immunohistochemical methods. Correlations involving HER-2/neu status, estrogen receptor (ER) and progesterone receptor (PR) status, tumor grade, patient age, lymph node involvement, and tumor size were evaluated using the Mantel-Haenszel chi-square test and the Spearman correlation. The authors created a simple scoring system (i.e., the diagnostic instrument for validation of HER-2/neu score) to define subgroups of patients with breast carcinoma and to determine the likelihood of HER-2/neu positivity.

RESULTS

HER-2/neu overexpression was correlated significantly with negative ER (P = 0.0001) and PR status (P = 0.0001), Grade 3 (G3) lesions (P = 0.0001), and young age (P = 0.006). The likelihood of HER-2/neu positivity in a patient with positive ER and PR status and G1/G2 disease was approximately 6.1%.

CONCLUSIONS

The authors demonstrated in a large patient series that HER-2/neu overexpression was associated with negative hormone receptor status, G3, and young age. In a subgroup of patients presenting with hormone-responsive and G1/G2 tumors, the likelihood of HER-2/neu overexpression was very small. Therefore, the assessment of HER-2/neu status in this subgroup of patients with breast carcinoma may be considered unnecessary, unless the role of HER-2/neu status in adjuvant treatment has been proven.

Authors+Show Affiliations

Department of Surgery, Vienna University Medical School, Vienna, Austria. susane.taucher@univie.ac.atNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

14669272

Citation

Taucher, Susanne, et al. "Do We Need HER-2/neu Testing for All Patients With Primary Breast Carcinoma?" Cancer, vol. 98, no. 12, 2003, pp. 2547-53.
Taucher S, Rudas M, Mader RM, et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer. 2003;98(12):2547-53.
Taucher, S., Rudas, M., Mader, R. M., Gnant, M., Dubsky, P., Bachleitner, T., Roka, S., Fitzal, F., Kandioler, D., Sporn, E., Friedl, J., Mittlböck, M., & Jakesz, R. (2003). Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer, 98(12), 2547-53.
Taucher S, et al. Do We Need HER-2/neu Testing for All Patients With Primary Breast Carcinoma. Cancer. 2003 Dec 15;98(12):2547-53. PubMed PMID: 14669272.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Do we need HER-2/neu testing for all patients with primary breast carcinoma? AU - Taucher,Susanne, AU - Rudas,Margaretha, AU - Mader,Robert M, AU - Gnant,Michael, AU - Dubsky,Peter, AU - Bachleitner,Thomas, AU - Roka,Sebastian, AU - Fitzal,Florian, AU - Kandioler,Daniela, AU - Sporn,Emanuel, AU - Friedl,Josef, AU - Mittlböck,Martina, AU - Jakesz,Raimund, PY - 2003/12/12/pubmed PY - 2004/1/6/medline PY - 2003/12/12/entrez SP - 2547 EP - 53 JF - Cancer JO - Cancer VL - 98 IS - 12 N2 - BACKGROUND: HER-2/neu is a valuable prognostic marker in primary breast carcinoma. Controversy surrounds the correlation between HER-2/neu expression and other prognostic markers, as has been discussed in preclinical and clinical studies. The objective of the current study was to investigate the probability, calculated using parameters that are assessed routinely in clinical practice, that patients with breast carcinoma had positive HER-2/neu status. METHODS: The authors evaluated HER-2/neu status in 923 consecutive patients with breast carcinoma by immunohistochemical methods. Correlations involving HER-2/neu status, estrogen receptor (ER) and progesterone receptor (PR) status, tumor grade, patient age, lymph node involvement, and tumor size were evaluated using the Mantel-Haenszel chi-square test and the Spearman correlation. The authors created a simple scoring system (i.e., the diagnostic instrument for validation of HER-2/neu score) to define subgroups of patients with breast carcinoma and to determine the likelihood of HER-2/neu positivity. RESULTS: HER-2/neu overexpression was correlated significantly with negative ER (P = 0.0001) and PR status (P = 0.0001), Grade 3 (G3) lesions (P = 0.0001), and young age (P = 0.006). The likelihood of HER-2/neu positivity in a patient with positive ER and PR status and G1/G2 disease was approximately 6.1%. CONCLUSIONS: The authors demonstrated in a large patient series that HER-2/neu overexpression was associated with negative hormone receptor status, G3, and young age. In a subgroup of patients presenting with hormone-responsive and G1/G2 tumors, the likelihood of HER-2/neu overexpression was very small. Therefore, the assessment of HER-2/neu status in this subgroup of patients with breast carcinoma may be considered unnecessary, unless the role of HER-2/neu status in adjuvant treatment has been proven. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/14669272/Do_we_need_HER_2/neu_testing_for_all_patients_with_primary_breast_carcinoma L2 - https://doi.org/10.1002/cncr.11828 DB - PRIME DP - Unbound Medicine ER -